Limits...
Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.

Li Y, Pan K, Liu LZ, Li YQ, Gu MF, Zhang H, Shen WX, Xia JC, Li JJ - PLoS ONE (2015)

Bottom Line: The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006).In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients.This study provides a basis for alternative therapeutic strategies for metastatic NPC.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Endoscopy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.

ABSTRACT
In this study, we investigated the efficacy of sequential cytokine-induced killer cell (CIK) immunotherapy with gemcitabine plus cisplatin (GC) regimen chemotherapy in metastatic nasopharyngeal carcinoma (NPC) patients. Between September 2006 and April 2010, 222 NPC patients with distant metastasis after radiotherapy completion were retrospectively analyzed: 112 patients received 4-6 cycles of GC chemotherapy at 4-week intervals, followed by at least 4 cycles of CIK immunotherapy at 2-week intervals (GC+CIK group); the remaining 110 patients received 4-6 cycles of GC chemotherapy alone (GC group). The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006). In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients. This study provides a basis for alternative therapeutic strategies for metastatic NPC.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier survival curves during the 3-year follow-up period.Both progression free survival (PFS) (A) and overall survival (B) were better in Arm 1 (GC+CIK group, n = 112) than in Arm 2 (GC chemotherapy alone group, n = 110).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4476660&req=5

pone.0130620.g003: Kaplan-Meier survival curves during the 3-year follow-up period.Both progression free survival (PFS) (A) and overall survival (B) were better in Arm 1 (GC+CIK group, n = 112) than in Arm 2 (GC chemotherapy alone group, n = 110).

Mentions: In the GC+CIK group, the 1-, 2- and 3-year PFS rates were 76.0%, 32.1% and 23.8.0%, respectively, while in the GC group these rates were 70.0%, 24.5% and 17.0%, respectively (Fig 3A). The median PFS was 21 months in the GC+CIK group and 15 months in the GC group. There was a significant difference between the two groups (log-rank test, p = 0.009), with the GC+CIK group showing a significantly improved PFS rate compared with the GC group.


Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.

Li Y, Pan K, Liu LZ, Li YQ, Gu MF, Zhang H, Shen WX, Xia JC, Li JJ - PLoS ONE (2015)

Kaplan-Meier survival curves during the 3-year follow-up period.Both progression free survival (PFS) (A) and overall survival (B) were better in Arm 1 (GC+CIK group, n = 112) than in Arm 2 (GC chemotherapy alone group, n = 110).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4476660&req=5

pone.0130620.g003: Kaplan-Meier survival curves during the 3-year follow-up period.Both progression free survival (PFS) (A) and overall survival (B) were better in Arm 1 (GC+CIK group, n = 112) than in Arm 2 (GC chemotherapy alone group, n = 110).
Mentions: In the GC+CIK group, the 1-, 2- and 3-year PFS rates were 76.0%, 32.1% and 23.8.0%, respectively, while in the GC group these rates were 70.0%, 24.5% and 17.0%, respectively (Fig 3A). The median PFS was 21 months in the GC+CIK group and 15 months in the GC group. There was a significant difference between the two groups (log-rank test, p = 0.009), with the GC+CIK group showing a significantly improved PFS rate compared with the GC group.

Bottom Line: The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006).In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients.This study provides a basis for alternative therapeutic strategies for metastatic NPC.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China; Department of Endoscopy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.

ABSTRACT
In this study, we investigated the efficacy of sequential cytokine-induced killer cell (CIK) immunotherapy with gemcitabine plus cisplatin (GC) regimen chemotherapy in metastatic nasopharyngeal carcinoma (NPC) patients. Between September 2006 and April 2010, 222 NPC patients with distant metastasis after radiotherapy completion were retrospectively analyzed: 112 patients received 4-6 cycles of GC chemotherapy at 4-week intervals, followed by at least 4 cycles of CIK immunotherapy at 2-week intervals (GC+CIK group); the remaining 110 patients received 4-6 cycles of GC chemotherapy alone (GC group). The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006). In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients. This study provides a basis for alternative therapeutic strategies for metastatic NPC.

No MeSH data available.


Related in: MedlinePlus